Introduction
Recombinant viral vectors provide an effective means for heterologous antigen expression in vivo and thus represent promising platforms for developing novel vaccines against human pathogens such as Ebola virus, human immunodeficiency virus (HIV), tuberculosis, and malaria [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Preclinical evaluation of http://dx.doi.org/10.1016/j.vaccine.2016.06.071 0264-410X/Published by Elsevier Ltd.
q The findings, opinions, conclusions, and assertions contained in this consensus document are those of the individual members of the Working Group. They do not necessarily represent the official positions of any participant's organization (e.g., government, university, or corporations) and should not be construed to represent any Agency determination or policy. such viral vector vaccines has indicated their potential for immunization and an increasing number of candidate vaccines are entering human clinical trials. Improving our ability to anticipate potential safety issues and meaningfully assess or interpret safety data from trials of such new viral vector vaccines will increase their likelihood of public acceptance should they be licensed [11] [12] [13] [14] .
The Brighton Collaboration (www.brightoncollaboration.org) was formed in 2000 as an international voluntary collaboration to enhance the science of vaccine safety research [15] . In recognition of these needs in this domain, the Brighton Collaboration created the Viral Vector Vaccines Safety Working Group (V3SWG) in October 2008. Analogous to the value embodied in standardized case definitions for Adverse Events Following Immunization (AEFI), the V3SWG believes a standardized template describing the key characteristics of a novel vaccine vector, when completed and maintained with the latest research, will facilitate the scientific discourse among key stakeholders by increasing the transparency and comparability of information. The International AIDS Vaccine Initiative (IAVI) had already developed an internal tool to assess the risk/benefit of different viral vectors under its sponsorship. The IAVI graciously shared this tool with the V3SWG for adaptation and broader use as a standardized template for collection of key information for risk/benefit assessment on any viral vector vaccines. This tool was aimed at identifying potential major hurdles or gaps that would need to be addressed during the development of vectored vaccines. The template collects information on the characteristics of the wild type virus from which the vector was derived as well as known effects of the proposed vaccine vector in animals and humans, manufacturing features, toxicology and potency, nonclinical studies, and human use, with an overall adverse effect and risk assessment.
The V3SWG anticipates that eventually all developers/researchers of viral vector vaccines (especially those in clinical development) will complete this template and submit it to the V3SWG and Brighton Collaboration for peer review and eventual publication in Vaccine. Following this, to promote transparency, the template will be posted and maintained on the Brighton Collaboration website for use/reference by various stakeholders. Furthermore, recognizing the rapid pace of new scientific developments in this domain (relative to AEFI case definitions), we hope to maintain these completed templates ''wiki-" style with the help of Brighton Collaboration and each vectored vaccine community of experts [16] .
Need for risk/benefit assessment of live virus vaccines based upon a vesicular stomatitis virus (VSV) backbone
Vesicular stomatitis virus (VSV), a negative sense RNA virus of the Rhabdoviridae family, has become a prominent tool as a vaccine vector against microbial pathogens [17] . Desirable properties of recombinant VSV (rVSV) include robust growth in approved, continuous mammalian cell lines and the inherent ability to elicit strong cellular and humoral immune responses. Importantly, some highly attenuated forms of rVSV show no signs of virulence in animals, and attenuated, replication competent forms of rVSV have now demonstrated safety and immunogenicity in multiple clinical trials, specifically HIV Vaccine Trial Network (HVTN) 087 and 090 [18] . In animals, pathogenicity and immunogenicity has been largely attributed to the VSV glycoprotein (VSV G) [19, 20] with decreased or no infection achieved when the VSV G gene has been modified [21] . These factors, in combination with a very low seroprevalence of VSV in humans, support the use of rVSV as potential vaccine vectors, as discussed below.
Low seroprevalence in humans
While the natural hosts of VSV are insects and livestock, a few incident cases have occurred in humans as a result of high-risk occupational exposure (i.e. laboratory workers, farmers, veterinarians) [22, 23] . Infected humans may be asymptomatic or may experience a mild febrile illness with symptoms lasting 2-5 days [23] . The low incidence of infection and disease results in an overall very low level of pre-existing immunity to the virus among the general human population. Areas of exception include rural communities of Central America where both predominant serotypes VSV-New Jersey (VSV-NJ) and VSV-Indiana (VSV-IN) are endemic [24, 25] . Other areas of note include the enzootic regions of coastal Georgia where seroprevalence of humans to VSV-NJ was approximated at 30% in the early 20th century [26] .
Gene expression
Viral vector vaccines should demonstrate stability of foreign gene expression to ensure high-level expression of the target antigen(s). VSV has a simple genome of 11 KB encoding five major proteins. Transcriptional attenuation of approximately 30% occurs at each successive gene junction resulting in a pronounced 3' to 5' gradient of gene expression [27] [28] [29] [30] . Therefore, the genomic site of foreign gene insertion strongly influences antigen expression levels. Minimal conserved nucleotide sequences (transcription start and stop signals) are required for normal gene expression [31] and foreign gene inserts must be flanked by these sequence elements.
Although there are no apparent structural limitations on the size of foreign gene insert for the VSV vector, larger inserts appear to reduce the rate of viral replication in animal models. For example, rVSVGagEnv encoding both the HIV envelope (Env) and group specific antigen protein (Gag) contributing approximately 4.4 kilobases (kb) of additional genomic sequence, modestly reduced viral titers by threefold [32] . Since then, a larger insert of approximately 6 kb encoding Hepatitis C virus non-structural proteins (NS) has been expressed by a rVSV NJ vector, leading to a fivefold reduction in viral titer [33] . It is, however, also likely that some foreign gene products may further inhibit rVSV replication by other mechanisms such as biological activity, targeting and transport, or unforeseen toxicity.
Attenuation strategies
The pathogenicity of VSV has been attributed in part to the glycoprotein (VSV G), as virulence is dependent on the ability of G protein to bind cellular receptors, and mediate entry and fusion with endocytic vesicles to initiate the replicative cycle [34] . Due to pivotal roles in receptor binding and membrane fusion, it has been a target for attenuation of rVSV vector vaccines. Replacement of the G gene with that of another foreign gene product acting as a viral receptor can generate rVSVDG pseudotypes with altered cell tropism, which may also have attenuating effects. Foreign glycoproteins expressed by these pseudotypes are prime targets for cell-mediated and humoral immunity [35, 36] . Thus far, rVSV and rVSVDG vectors expressing influenza hemagglutinin (HA) and Ebola/Marburg glycoproteins have demonstrated full protection against virus challenge and are non-pathogenic in mouse and non-human primate (NHP) disease models [37] [38] [39] [40] [41] [42] [43] [44] . The strategy of using rVSV pseudo-typed with Ebola virus GP as a vaccine to combat Ebola virus induced disease has recently completed clinical testing and will be discussed in a separate vector analysis template due to the unique properties of the vector conferred by the Ebola virus GP protein as sole virus receptor. In vitro and in vivo attenuation of rVSV has also been demonstrated by truncation of the cytoplasmic tail (CT) of the G protein from 29 amino acids found in nature, to only 9 or 1 amino acids (CT9 and CT1 respectively) [17, 42, 45] . It is generally thought that this attenuation mechanism acts by impairing the interaction of the G CT with underlying viral core proteins, thereby reducing the efficiency of virus particle maturation and budding.
Another major approach to rVSV attenuation relies on downregulation of expression of one or more key viral structural proteins. This attenuation strategy has been demonstrated for rVSV by translocation of the N gene further away from the 3' transcription promoter to positions 2, 3 and 4 in the genome [28, 29] . The resulting step-wise reduction in N protein expression leads to corresponding incremental reduction of viral replication in vitro and reduced pathogenesis in a natural host [30] .
Attenuation by either CT truncation or N gene translocation separately could not provide sufficient reduction in neuropathology in stringent murine and NHP neurovirulence (NV) models to support testing of rVSV as a vaccine vector in humans [46] [47] [48] . However, when both forms of attenuation were combined there was a dramatic and synergistic increase in vector attenuation, almost completely eliminating clinical and microscopic pathology following intra-cranial injection of mice and NHPs [47, 49, 50] .
One additional attenuation mechanism relies on either mutation or deletion of amino-acid 51 of the VSV M protein These VSV M mutants grow quite robustly in cell culture but demonstrate a marked reduction of virulence in vivo. It is thought that the attenuating mutation(s) reduce the ability of virus to shut down host innate immune responses which normally restrict virus growth in vivo [51-53].
Post exposure protection
Studies using rVSVDG vectors expressing Ebola and Marburg virus glycoproteins achieved post-exposure prophylaxis in both rodent and NHP models [20] . If administered in one dose within 24 h of virus challenge, 50-100% of both guinea pigs and mice were protected. Similarly, there was 50% protection of NHPs if treatment was administered within 30 min of challenge.
Clinical trials
A live viral vaccine safety standard for all licensed vaccines requires assessment of viral NV by intracranial inoculation of NHPs with the vaccine [54, 55] . Vaccines for measles, mumps, yellow fever, polio and others have all been assessed for NV by this method [56] [57] [58] [59] . A pilot NV study in NHPs demonstrated that prototypic rVSV vectors expressing HIV gag and env were not adequately attenuated for clinical evaluation [48] . However, extensive testing in mouse NV studies and two additional, sequential NHP NV studies led to the identification of rVSV vectors that were safe for clinical testing [49, 50] ); one of these highly attenuated vectors known as rVSVN4CT1gag1 was selected for a first in man clinical trial. The rVSVN4CT1gag1vector was attenuated by translocation of the N gene to the 4th position in the genome (N4), truncation of the G protein CT to a single amino acid (CT1) and the gag gene was located in the 1st position of the genome (gag1) to maximize gag protein expression. The rVSVN4CT1gag1 vector has now demonstrated safety and immunogenicity in phase 1 clinical trials [18] and the rVSVN4CT1 expressing Ebola virus GP is on a clinical development pathway as a candidate Ebola virus vaccine [41] .
To provide clinical trial materials (CTM) for Phase 1 studies, an HIV-1 vaccine production process was developed in a 10L bioreactor under good manufacturing practices (GMP). An approved Vero cell line was used as substrate for vaccine vector amplification. Following infection, culture medium from infected cells was harvested once cell cytopathology was extensive (80-100%), and centrifuged to remove cellular debris. This unprocessed harvest material (UHM) was then conditioned with a virus stabilizer at a final concentration of 7.5% sucrose, 3.8 mM KH 2 PO 4 , 7.2 mM K 2 HPO 4 and 5 mM L-Glutamate (SPG) and passed through an anion exchange membrane which binds rVSV particles. The membrane was then rinsed to remove cellular proteins, and DNA and virus particles were eluted in a high salt buffer. The high salt eluate was exchanged with a low salt phosphate buffer suitable for injection by a process of tangential flow ultra-filtration. The resulting virus preparation was then formulated with SPG and 0.2% hydrolyzed gelatin as additional virus stabilizer, sterile-filtered, and dispensed in vials as drug product (also known as CTM). CTM was stored frozen at À70°C to À80°C until ready for injection. CTM material generated by this process (or equivalent material generated by the same process) underwent toxicology testing in rabbits under GMP. Data from the toxicology study, the results of compendial safety tests performed at all key stages of vaccine manufacturing, and all data from pre-clinical development and safety testing of the rVSVN4CT1gag1 vector, were submitted to the FDA as part of an investigational new drug (IND) application in 2011. The FDA approved the rVSVN4CT1gag1 vector for clinical evaluation, and enrollment for HVTN 090, a Phase 1, double blinded, placebo controlled clinical trial began in October 2011, marking the first time an rVSV vaccine vector was administered to healthy trial participants. Data from this first in human trial have now been published [18] . The rVSVN4CT1gag1 vector has also demonstrated safety and immunogenicity in a second HIV-1 Phase 1 clinical trial as part of a pDNA prime, rVSV boost, vaccination regimen (HVTN 087: http://clinicaltrials.gov/).
Future directions
The safety and immunogenicity of the rVSVN4CT1gag1 vector in animal models and in clinical trials has demonstrated the potential of rVSV vectors targeting other infectious diseases. Robust and stable gene expression, a safe, attenuated phenotype, and induction of foreign antigen-specific immune responses, support further development of rVSV and other vesiculoviruses as platforms for vaccine development.
Methods for developing, completing, and reviewing the standardized template
Following the process described earlier, [60] as well as on the Brighton Collaboration Website (http://cms.brightoncollaboration. org:8080/public/what-we-do/setting-standards/case-definitions/ process.html), the Brighton Collaboration V3SWG was formed in October 2008 and includes $15 members with clinical, academic, public health, regulatory and industry backgrounds with appropriate expertise and interest. The composition of the working and reference group, as well as results of the web-based survey completed by the reference group with subsequent discussions in the working group, can be viewed at http://www.brightoncollaboration.org/internet/en/index/workinggroups.html. The workgroup meets via emails and monthly conference calls coordinated by a secretariat [15] .
The V3SWG invited a VSV expert, David K. Clarke (DKC), who has been intimately associated with the development of vaccines based on highly attenuated rVSV vectors, to complete the template. The draft was then reviewed by the V3SWG. DKC updated the template with new information prior to publication. The resulting template is submitted as a guideline for evaluating the current issues in development of vaccines based on replicating VSV vectors. The purification process has been validated and documented. One impurity identified are HIV-1 Gag virus like particles (VLP) composed of Gag protein expressed by rVSV. The Gag VLP is present in CTM at very low levels and does not influence the magnitude of Gag-specific immune responses
Standardized template (
Another impurity is host cell DNA. The level of contaminating DNA is low (<50 ng/vaccine dose) and the bulk of contaminating Vero cell DNA is composed of small DNA fragments <500 bp in length, and is therefore not considered a significant safety issue
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